That's the problem with citing micro-studies - the sample sizes, presence (or lack of) of academic protocols, studies in relation to proper control groups, etc. If any of these are lacking then the study results are/and should be cancelled to ensure correct outcomes.
To that end, CMI (Clinical Microbiology and Infection is a monthly publication in English of the European Society of Clinical Microbiology and Infectious Diseases and publishes peer-reviewed papers that present basic and applied research relevant to therapy and diagnostics in the fields of microbiology, infectious) conducted a meta-data analysis with the aim:
"The aim of this systematic review and meta-analysis was to assess whether chloroquine or hydroxychloroquine with or without azithromycin decreased COVID-19 mortality compared with the standard of care."
This drew in sources from PubMed, Web of Science, Embase Cochrane Library, Google Scholar and MedRxiv were searched up to 25 July 2020.
The result of the meta-data study?
"Hydroxychloroquine alone was not associated with reduced mortality in hospitalized COVID-19 patients but the combination of hydroxychloroquine and azithromycin significantly increased mortality."
From a science-based view, that's probably the end of the HCQ discussion.
https://www.clinicalmicrobiologyandi...505-X/fulltext